BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29770533)

  • 21. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
    Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
    Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years.
    Zhou J; Ren Y; Tan L; Song X; Wang M; Li Y; Cao Z; Guo C
    Biomed Pharmacother; 2020 Nov; 131():110755. PubMed ID: 33152920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
    Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
    Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Norcantharidin induces apoptosis in HeLa cells through caspase, MAPK, and mitochondrial pathways.
    An WW; Gong XF; Wang MW; Tashiro S; Onodera S; Ikejima T
    Acta Pharmacol Sin; 2004 Nov; 25(11):1502-8. PubMed ID: 15525474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of norcantharidin, a protein phosphatase type-2A inhibitor, on the growth of normal and malignant haemopoietic cells.
    Liu XH; Blazsek I; Comisso M; Legras S; Marion S; Quittet P; Anjo A; Wang GS; Misset JL
    Eur J Cancer; 1995 Jun; 31A(6):953-63. PubMed ID: 7646929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NCTD elicits proapoptotic and antiglycolytic effects on colorectal cancer cells via modulation of Fam46c expression and inhibition of ERK1/2 signaling.
    Zhang S; Yang Y; Hua Y; Hu C; Zhong Y
    Mol Med Rep; 2020 Aug; 22(2):774-782. PubMed ID: 32468032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.
    Qiu P; Wang S; Liu M; Ma H; Zeng X; Zhang M; Xu L; Cui Y; Xu H; Tang Y; He Y; Zhang L
    BMC Cancer; 2017 Jan; 17(1):55. PubMed ID: 28086832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effector mechanisms of norcantharidin-induced mitotic arrest and apoptosis in human hepatoma cells.
    Chen YN; Chen JC; Yin SC; Wang GS; Tsauer W; Hsu SF; Hsu SL
    Int J Cancer; 2002 Jul; 100(2):158-65. PubMed ID: 12115564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Norcantharidin Enhances High Concentrations of Fetal Bovine Serum-Induced Apoptosis in Human Mesangial Cells by Regulating the Mitogen-Activated Protein Kinase Signaling Pathway.
    Ye K; Wei QY; Long TX; He HG; Huang YF; Xiong LJ; Lan J; Huang YY; Gong ZF; Peng XM; Wu QX
    Kidney Blood Press Res; 2019; 44(6):1339-1351. PubMed ID: 31661692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
    Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
    Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer.
    Li XY; Guan QX; Shang YZ; Wang YH; Lv SW; Yang ZX; Wang R; Feng YF; Li WN; Li YJ
    World J Gastroenterol; 2021 Jul; 27(26):4208-4220. PubMed ID: 34326620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma.
    Jiang S; Li M; Hu Y; Zhang Z; Lv H
    Carbohydr Polym; 2018 Oct; 197():194-203. PubMed ID: 30007605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
    Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Norcantharidin triggers cell death and DNA damage through S-phase arrest and ROS-modulated apoptotic pathways in TSGH 8301 human urinary bladder carcinoma cells.
    Yu CC; Ko FY; Yu CS; Lin CC; Huang YP; Yang JS; Lin JP; Chung JG
    Int J Oncol; 2012 Sep; 41(3):1050-60. PubMed ID: 22684608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells.
    Ye K; Wei Q; Gong Z; Huang Y; Liu H; Li Y; Peng X
    Ren Fail; 2017 Nov; 39(1):458-464. PubMed ID: 28393592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norcantharidin blocks Wnt/β-catenin signaling via promoter demethylation of WIF-1 in glioma.
    Xie D; Xie J; Wan Y; Ma L; Qi X; Wang K; Yang S
    Oncol Rep; 2016 Apr; 35(4):2191-7. PubMed ID: 26781164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
    Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of norcantharidin on angiogenesis of human gallbladder carcinoma and its anti-angiogenic mechanisms].
    Fan YZ; Chen CQ; Zhao ZM; Sun W
    Zhonghua Yi Xue Za Zhi; 2006 Mar; 86(10):693-9. PubMed ID: 16681930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.